Pasquale Rescigno, Nuria Porta, Laura Finneran, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Penny Flohr, Susana Miranda, Claudia Bertan, Ana Ferreira, Mateus Crespo, Daniel Nava Rodrigues, Bora Gurel, Jenny Nobes, Simon Crabb, Zafar Malik, Christy Ralph, Ursula McGovern, Peter Hoskin, Robert J Jones, Alison Birtle, Joanna Gale, Peter Sankey, Suneil Jain, Duncan McLaren, Eliot Chadwick, Aude Espinasse, Emma Hall, Johann de Bono
BACKGROUND: PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). In this study, we assessed antitumor activity of the AKT inhibitor capivasertib combined with enzalutamide in mCRPC with prior progression on AA and docetaxel. METHODS: This double-blind, placebo-controlled, randomized phase 2 trial, recruited men ≥ 18 years with progressing mCRPC and performance status 0-2 from 15 UK centers...
May 8, 2024: European Journal of Cancer